Monitoring DKK1 levels in circulation and in the TME, and DKK1 neutralization should be considered to improve the therapeutic response of NK-based strategies and/or the limited efficacy of immunotherapies in breast cancer. This evidence concerns the gene DKK1 and breast carcinoma.